EtO Reconsideration Does Not Remove The Need For Sterilization Optionality

**On May 1, 2026, the EPA published an extension of the public comment period for its proposed reconsideration of the 2024 ethylene oxide emissions standards.** The comment period now closes May 15, 2026. The extension is a procedural step in an active federal rulemaking process — one that has been unresolved for over two years and shows no indication of reaching a stable conclusion in the near term.

For medical device manufacturers evaluating sterilization strategy, the regulatory environment around EtO has now been in motion long enough to function as an independent variable in capital planning. Whether the final rule tightens, softens, or is replaced by a different framework, the period of regulatory predictability that characterized EtO sterilization infrastructure from 2000 to 2019 has ended. That structural change is more consequential than the direction of any single rulemaking.

What The Reconsideration Actually Says

The EPA proposed in March 2026 to reconsider — and potentially repeal — the Biden-era National Emission Standards for Hazardous Air Pollutants rule for commercial EtO sterilization facilities, published in April 2024. The 2024 rule required commercial EtO facilities to implement emissions controls achieving 90%+ reductions in EtO air releases — a standard that required significant capital investment in scrubbers, enclosures, and monitoring infrastructure.

The March 2026 proposed reconsideration cited supply chain concerns: ethylene oxide sterilizes approximately 50% of all U.S. medical devices annually — an estimated 20 billion devices — including implantables, combination products, and single-use surgical instruments whose material characteristics preclude steam sterilization. The EPA's stated position was that the 2024 rule's compliance requirements created near-term risks to domestic medical device availability.

The proposed reconsideration would give facilities a choice between installing new monitoring systems or making certain adjustments to aeration room venting — a narrower compliance burden than the 2024 rule. The May 1, 2026 Federal Register notice extended the comment period for public input on that proposal to May 15, 2026.

What The Reconsideration Does Not Change

The proposed reconsideration addresses emission control requirements at commercial sterilization facilities. It does not address several of the underlying structural conditions that have made EtO sterilization dependency a strategic liability for device manufacturers:

**EtO's carcinogen classification is unchanged.** The EPA classifies ethylene oxide as a known human carcinogen. Recent risk modeling — including 2024 studies indicating EtO is approximately 60% more carcinogenic than previously estimated — has not been withdrawn or revised as part of the reconsideration. Whether the emission control thresholds are set at the 2024 level or a lower level, the underlying hazard classification remains.

**Community and legal opposition to EtO facility permitting continues.** In multiple U.S. states, EtO sterilization facility permitting has faced community opposition, litigation, and state-level regulatory actions that operate independently of federal EPA rulemaking. Illinois, Georgia, and New Mexico have each seen facility-specific EtO conflicts in the past five years. State-level opposition has resulted in facility closures, capacity reductions, and operational restrictions that federal reconsideration does not preempt.

**Occupational exposure liability has not been resolved.** The regulatory debate concerns airborne emissions to surrounding communities. The occupational exposure question — what levels of EtO exposure are acceptable for sterilization facility workers — is governed by OSHA standards that are not part of the EPA reconsideration and represent a separate and ongoing liability vector for facilities that process product using EtO.

**Capital investments already made are sunk.** EtO facilities that invested in the abatement infrastructure required by the 2024 rule in the period between publication and the 2026 reconsideration did not make those investments speculatively — they made them under a regulatory mandate that was in effect. Those investments are reflected in the cost structure those facilities now carry, and they have already produced pricing changes that have not been reversed. The per-unit cost of contract EtO sterilization is structurally higher than it was in 2022.

The Strategic Problem Is Volatility Itself

The conventional framing of the EtO situation presents it as a question with a pending answer: will emission standards be tight or loose? That framing treats the regulatory environment as having an eventual equilibrium that manufacturers should wait to observe before making capital decisions.

The evidence from the past six years does not support that model. The EtO regulatory environment has moved from a proposed rule (2023) to a final rule (2024) to a proposed reconsideration (March 2026) to an extended comment period (May 2026) — with an outcome that is not currently determinable and will likely be subject to further legal and regulatory challenge regardless of what the final rule says. Manufacturers who have treated this sequence as temporary noise to be waited out have now held that position for six years.

Sterilization is a process-critical step in product release. The manufacturers exposed to the most risk are not those that use EtO — they are those that use EtO exclusively, without a validated alternative. The strategic problem is dependency under conditions of regulatory volatility, not the current regulatory position.

VHP Is Not A Contingency Plan

The argument for validated VHP sterilization capability is not reactive. FDA's January 2024 Category A reclassification placed VHP in the same regulatory tier as steam, EtO, and radiation — an established method with an established evidence base and a defined validation pathway under ISO 22441:2022. The VHP validation pathway is not experimental. It is a recognized, submission-ready framework that has been used to support FDA 510(k) and EU MDR submissions for several years.

For manufacturers with EtO-validated processes, the question is not whether VHP is acceptable — the FDA's Category A designation answers that question — but whether the organization has built the capability to use it. Building that capability is a capital and validation investment, typically six to twelve months from equipment procurement to a validated, submission-ready process for a single product configuration. That investment timeline means manufacturers who begin the work now will have validated optionality well before the current EtO regulatory proceedings reach resolution.

The supply chain resilience argument runs parallel to the regulatory one. Manufacturers with validated in-house VHP capability are not subject to contract sterilizer scheduling constraints, irradiation or EtO capacity bottlenecks, or the pricing dynamics of a cost-plus service model operating under regulatory-driven capital pressure. They own their sterilization process. That ownership produces a different risk profile from dependency on any external party's facility, compliance status, or pricing decisions.

The Informed Position

Manufacturers evaluating the current EtO regulatory situation have a decision to make that does not require waiting for the EPA's final position. The decision is whether to build validated sterilization optionality now, while the VHP pathway is well-established, the service ecosystem around ISO 22441 validation is mature, and the investment can be made on a deliberate timeline — or to build it later, under conditions of greater urgency.

The May 15, 2026 comment period deadline for the EPA's proposed reconsideration is a regulatory milestone. It is not a strategic inflection point for manufacturers who have already understood the structural argument for validated sterilization alternatives. For manufacturers who have not yet started that analysis, it is a useful prompt.

For context on the VHP validation lifecycle under ISO 22441, see [the full pathway analysis for device manufacturers](/insights/vhp-validation-pathway-device-manufacturers). The economic case for in-house sterilization — including cost-per-released-lot modeling against contract sterilization — is addressed in [the small manufacturer in-house analysis](/insights/in-house-vhp-sterilization-small-manufacturers).

Frequently Asked Questions

**What did the EPA actually propose in March 2026 regarding EtO sterilization?**

The EPA proposed reconsideration of the April 2024 National Emission Standards for Hazardous Air Pollutants rule governing commercial ethylene oxide sterilization facilities. The 2024 rule required facilities to implement emissions controls reducing EtO air releases by 90% or more. The proposed reconsideration would give facilities a choice between installing new monitoring systems or making adjustments to aeration room venting — a less capital-intensive compliance alternative. The comment period on that proposal was extended to May 15, 2026 by the May 1, 2026 Federal Register notice.

**Does the EPA reconsideration mean EtO regulations are loosening permanently?**

The reconsideration represents a proposed rule subject to the full notice-and-comment process, potential legal challenge, and future regulatory review. It does not reverse EtO's carcinogen classification, repeal state-level regulatory actions, or eliminate occupational exposure liability. The overall EtO regulatory trajectory — viewed across the full period from 2019 through 2026 — remains one of increased scrutiny, not reduced scrutiny. The current reconsideration is a deceleration in one regulatory dimension, not a return to pre-2019 conditions.

**How does VHP's FDA Category A status affect sterilization strategy for EtO users?**

FDA's January 2024 Category A reclassification means VHP sterilization can be submitted to FDA under the same evidentiary framework as EtO, steam, and radiation — with validation per ISO 22441:2022 and no requirement for method justification beyond the validated process package. For manufacturers with existing EtO-validated processes, a transition to or addition of VHP requires process validation for each product affected, typically a 510(k) or PMA supplement depending on device type. The regulatory pathway is defined and well-characterized; the principal investment is in validation execution.

**What is the realistic timeline for a manufacturer to build validated VHP capability?**

Six to twelve months from equipment procurement decision to a validated, submission-ready process is the established range for most product configurations under ISO 22441. The lower end applies to straightforward single-material products with available bioburden data and existing validation team infrastructure. Complex multi-material combination products, novel packaging requiring compatibility characterization, or organizations building validation capability in parallel with technical work fall toward the upper end. Beginning the analysis and procurement process in mid-2026 positions manufacturers to have validated VHP optionality well before the current EPA rulemaking reaches a final disposition.